Purpose: To report a novel synonymous mutation in CHM and the associated phenotype in an affected man and carrier mother.
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A novel synonymous mutation in CHM was identified in a patient with choroideremia and his carrier mother. To our knowledge, this is the first silent mutation identified in an exon of CHM associated with classic disease phenotype.
Choroideremia (CHM, OMIM 303100) is a rare Xlinked retinal degenerative disease-causing progressive blindness in approximately 1 in 50,000 individuals, with a particularly high prevalence in Finland. 1 Affected men typically present with night blindness followed by decreased peripheral vision and eventually severe blindness around the sixth decade of life. Visual acuity can be stable, and even remain 20/20, if degeneration does not involve the fovea. 2 The molecular etiology involves dysfunction of the CHM gene product, which encodes the Rab escort protein-1 (REP-1). REP-1 is believed to have an important role in protein transport in photoreceptors and the retinal pigment epithelium (RPE) through prenylation, a type of lipid modification, of Rab proteins in the retina. A buildup of unprenylated Rabs is hypothesized to cause the extensive chorioretinal degeneration that is observed clinically. 3 Fundoscopy typically shows pale fundi because of illumination of the sclera behind degenerated retinal layers. Peripheral thinning of the photoreceptor outer segments and loss of RPE on spectral domain optical coherence tomography (SD-OCT) with large corresponding areas of hypoautofluorescence on short-wavelength fundus autofluorescence (FAF) imaging are the most ubiquitous clinical presentation. 4 The phenotype of CHM is unique, allowing for expedient identification at specialized centers. 5 Almost all known pathogenic variants identified are null mutations, and direct sequencing of CHM can confirm the diagnosis. In fact, one retrospective analysis found that 94% of clinically diagnosed cases could be confirmed by directly sequencing the 15 exons and flanking intronic regions of CHM. 5 Studies seeking to analyze the mutation spectrum of CHM typically find most disease-causing variants to be nonsense mutations, followed by deletions. 5, 6 Large genomic rearrangements are frequent in CHM, which often necessitate additional assays for insertions and deletions. To date, analyses have revealed deletions, insertions, duplications, translocations, nonsense, splice-site, frameshift, and missense mutations in CHM. 6 Here, we present the first "silent," or synonymous, mutation associated with CHM and a pronounced carrier phenotype. This case report serves to identify a rare variant that is believed to be disease causing in a patient who could thus be considered for future gene-therapy trials.
Case Report
An otherwise healthy 34-year-old man of Cuban descent ( 
S68
examination showed a clear vitreous. There was extensive chorioretinal degeneration of the peripheral retina with scalloped preservation of the RPE in the central macula, bilaterally. No intraretinal pigment migration was observed; however, subretinal hyperpigmentation was present. In addition, peripheral regions of the fundus were pale (Table 1) . Fundus autofluorescence imaging revealed extensive RPE loss outside the central macula and peripapillary area. Spatially corresponding SD-OCT scans confirmed extensive outer retinal degeneration in these areas with evident RPE loss yielding increased reflective transmittance to the choroidal layers in areas of hypoautofluorescence on FAF (Figure 2) . The patient was referred for genetic screening of CHM at the Casey Eye Institute (Portland, OR) in accordance with the clinical findings. The genetic results were inconclusive and identified a novel hemizygous, synonymous mutation in exon 11, c.1359C.T, p.(S453S). Larger genomic aberrations in CHM were not detected in the proband using array comparative genome hybridization performed at Molecular Visions Laboratory (Hillsboro, OR). It was recommended for the mother to be evaluated.
The mother (Figure 1, II: 2) of the proband presented at 63 years old with no visual complaints. A medical history included arthritis and diabetes mellitus. An ocular history was unremarkable, except for a history of refractive surgery in both eyes. Vision was 20/30 bilaterally without correction. Slit-lamp examination of the anterior segment and fundoscopy was unremarkable (Table 1) . Spectral domain optical coherence tomography revealed intact retinal layers with intermittent areas of decreased reflectance in the RPE layer ( Figure 3) . The choroid was found to be thin, measuring 167 mm and 183 mm thick subfoveally in the right and left eyes, respectively. Fundus autofluorescence imaging revealed a mosaic pattern of patchy hypoautofluorescence in a fishnet pattern up to the parafoveal area (Figure 3 ), consistent with a CHM carrier phenotype. The patient was heterozygous for the c.1359C.T, p. (S453S) variant identified in the proband, confirming parental segregation.
Discussion
Choroideremia is one of the several inherited retinal dystrophies that have a specific phenotype-warranting candidate single-gene testing. With imminent Phase III clinical trials and ongoing natural history studies, identification of male patients harboring hemizygous CHM mutations has become increasingly important. The present case identifies the first synonymous mutation associated with choroideremia and illustrates how the genotypic spectrum of an inherited retinal dystrophy can be expanded by clinical correlation and assessment of family members. Although the identified c.1359C.T, p.(S453S) variant does not alter the predicted protein sequence, it alters the nucleotide sequence of the third codon of exon 11 (TCC to TCT), close to the flanking intron region. This nucleotide is weakly conserved (phyloP: 2.09 [−20.0; 10.0]); however, the effect is predicted to eliminate the binding site for the serine/arginine-rich splicing factor 1 (SF2/ ASF). Interestingly, noncoding variation within this region, namely c.1380-6T.G, c.1380-1G.A, and c.1350-1G.A, is reported to cause skipping or truncation of exon 11 and are associated with disease phenotype. 7, 8 The identified c.1359C.T variant is exceedingly rare in the general population because it has not been identified in 123,136 exome sequences and 15,496 whole-genome sequences (http://gnomad. broadinstitute.org/; accessed April 2017).
Presence of classic carrier signs in a mother who is heterozygous for this novel variant, further supports pathogenicity of this variant. The lyonization phenotype of heterozygous carriers in several X-linked retinal dystrophies is previously well characterized, including RPGR-associated retinitis pigmentosa, ocular albinism, and choroideremia. 9 Various mosaic-like patterns are observable in carrier females of these conditions because of neighboring cells expressing either functional or dysfunctional protein product, as a result of random X-chromosome inactivation or lyonization. Fundus autofluorescence imaging of the mother in our study showed an extensive patchy appearance of the fundus with areas of reticular hypo-and hyper-autofluorescence of the RPE in the macula. Subtle aberrations of the RPE were observed on SD-OCT along with thinning of the observable choroid. These features were without significant visual consequence and are consistent with previous reports and histopathologic studies. 4, [10] [11] [12] [13] However, axial and refractive status was not documented, which could explain the visual acuity and thin choroid on SD-OCT. Identification of a carrier phenotype on FAF imaging in this case allowed for expedient confirmation of the diagnosis.
Although a novel variant was found to segregate with specific features of choroideremia in this family, contribution of an additional or stronger variant within the same allele remains possible as candidate gene sequencing cannot routinely detect large insertions or deletions in the gene. Negative findings from the array comparative genome hybridization test decrease the probability of this occurrence, although further assessment of this synonymous variant with a REP1 prenylation assay and mRNA sequencing (RNA-seq and splicing assays) may further elucidate its pathogenicity. Patients with this variant may benefit from traditional gene-based therapies, as the approach involves supplementing target cells with a wild-type copy of the gene. Choroideremia is already being approached in clinical trials with conventional gene therapy. 14 Each trial uses an adeno-associated viral vector delivering functional CHM. Initial results from one of the Phase I/IIa clinical trials suggest gene therapy for choroideremia is safe. Furthermore, all patients had increased retinal sensitivity in the treated area of the retina in a vector dosage-dependent manner. 2 Patients with the c.1359C.T, p.(S453S) variant, and a classic choroideremia phenotype should be considered for enrollment into treatment trials.
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